Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Samuel Martín-Vílchez
268  Ergebnisse:
Personensuche X
?
1

Genetic variation in UGT1A1 is not associated with altered ..:

González-Iglesias, Eva ; Ochoa, Dolores ; Román, Manuel...
Frontiers in Pharmacology.  15 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
2

Impact of Sex and Genetic Variation in Relevant Pharmacogen..:

Soria-Chacartegui, Paula ; Zubiaur, Pablo ; Ochoa, Dolores...
International Journal of Molecular Sciences.  24 (2023)  20 - p. 15265 , 2023
Link: https://doi.org/10.3390/..
 
?
3

Impact of polymorphisms in CYP and UGT enzymes and ABC and ..:

Calleja, Sofía ; Zubiaur, Pablo ; Ochoa, Dolores...
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
4

NAT2 phenotype alters pharmacokinetics of rivaroxaban in he..:

Villapalos-García, Gonzalo ; Zubiaur, Pablo ; Ochoa, Dolores...
Biomedicine & Pharmacotherapy.  165 (2023)  - p. 115058 , 2023
Link: https://doi.org/10.1016/..
 
?
5

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine ..:

Soria-Chacartegui, Paula ; Zubiaur, Pablo ; Ochoa, Dolores...
Pharmaceutics.  15 (2023)  2 - p. 404 , 2023
Link: https://doi.org/10.3390/..
 
?
6

Food Administration and Not Genetic Variants Causes Pharmac..:

Villapalos-García, Gonzalo ; Zubiaur, Pablo ; Marián-Revilla, Cristina...
Journal of Personalized Medicine.  13 (2023)  11 - p. 1566 , 2023
Link: https://doi.org/10.3390/..
 
?
7

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine ..:

Paula Soria-Chacartegui ; Pablo Zubiaur ; Dolores Ochoa...
https://www.mdpi.com/1999-4923/15/2/404.  , 2023
Link: https://doi.org/10.3390/..
 
?
8

NAT2 phenotype alters pharmacokinetics of rivaroxaban in he..:

Gonzalo Villapalos-García ; Pablo Zubiaur ; Dolores Ochoa...
http://www.sciencedirect.com/science/article/pii/S075333222300848X.  , 2023
Link: https://doi.org/10.1016/..
 
?
9

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine ..:

Paula Soria-Chacartegui ; Pablo Zubiaur ; Dolores Ochoa...
Clinical Pharmaceutics.  , 2023
Link: https://doi.org/10.3390/..
 
?
10

Table1_Impact of polymorphisms in CYP and UGT enzymes and A..:

Sofía Calleja ; Pablo Zubiaur ; Dolores Ochoa...
doi:10.3389/fphar.2023.1110460.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Impact of Sex and Genetic Variation in Relevant Pharmacogen..:

Paula Soria-Chacartegui ; Pablo Zubiaur ; Dolores Ochoa...
https://www.mdpi.com/1422-0067/24/20/15265.  , 2023
Link: https://doi.org/10.3390/..
 
?
12

Impact of polymorphisms in CYP and UGT enzymes and ABC and ..:

Sofía Calleja ; Pablo Zubiaur ; Dolores Ochoa...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1110460/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Polymorphism of Drug Transporters, Rather Than Metabolizing..:

Zubiaur, Pablo ; Matas, Miriam ; Martín-Vílchez, Samuel...
Pharmaceutics.  14 (2022)  10 - p. 2001 , 2022
Link: https://doi.org/10.3390/..
 
?
14

First-in-human phase I clinical trial of a TLR4-binding DNA..:

Hernández-Jiménez, Macarena ; Martín-Vílchez, Samuel ; Ochoa, Dolores...
Molecular Therapy - Nucleic Acids.  28 (2022)  - p. 124-135 , 2022
Link: https://doi.org/10.1016/..
 
?
15

First-in-human phase I clinical trial of a TLR4-binding DNA..:

Macarena Hernández-Jiménez ; Samuel Martín-Vílchez ; Dolores Ochoa...
http://www.sciencedirect.com/science/article/pii/S2162253122000543.  , 2022
Link: https://doi.org/10.1016/..
 
1-15